Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | TP53 R181L |
Therapy | Doxorubicin + Nutlin-3a |
Indication/Tumor Type | lung adenocarcinoma |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
TP53 R181L | lung adenocarcinoma | sensitive | Doxorubicin + Nutlin-3a | Preclinical - Cell culture | Actionable | In a preclinical study, a lung adenocarcinoma cell line expressing TP53 R181L demonstrated enhanced sensitivity to Adriamycin (doxorubicin) treatment when combined with Nutlin-3, and induced apoptosis in culture (PMID: 31483066). | 31483066 |
PubMed Id | Reference Title | Details |
---|---|---|
(31483066) | Residual apoptotic activity of a tumorigenic p53 mutant improves cancer therapy responses. | Full reference... |